A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Renal Function

Trial Profile

A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Renal Function

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Sponsors CoLucid Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2017 Status changed from recruiting to completed.
    • 16 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 01 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top